ViroGates A/S
CSE:VIRO
Net Margin
ViroGates A/S
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
DK |
V
|
ViroGates A/S
CSE:VIRO
|
76.9m DKK |
-276%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
229.2B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.1B USD |
29%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
152.7B USD |
14%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
146B USD |
12%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
119.2B USD |
14%
|
|
CN |
H
|
Hongchang International Co Ltd
OTC:HCIL
|
103.8m USD |
-8%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
52.8B EUR |
9%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
56.2B USD |
7%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.2B USD |
24%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
45.9B USD |
73%
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ViroGates A/S's most recent financial statements, the company has Net Margin of -276.1%.